- Scienture Holdings (SCNX, Financial) announces manufacturing readiness for Arbli™, the only FDA-approved ready-to-use liquid losartan in the U.S.
- Arbli™ targets a $292 million losartan market with a launch set for July 2025.
- Strategic manufacturing and distribution partnerships are in place, supporting a successful product launch.
Scienture Holdings, Inc. (SCNX) has confirmed the manufacturing and supply chain readiness for the launch of Arbli™, their FDA-approved oral liquid losartan suspension. The preparation marks a significant step towards the product's intended commercial debut in July 2025. Arbli™ stands out as the first liquid formulation of losartan in the U.S., catering to patients requiring a liquid option for hypertension treatment.
The company's subsidiary has partnered with Saptalis Pharmaceuticals, ensuring the necessary materials and capabilities are in place to produce the launch quantities. Strategic agreements for warehousing and distribution have also been secured, positioning Scienture for an efficient market entry.
Aiming at a considerable market opportunity, Scienture targets the $292 million U.S. losartan market, which sees 68 million prescriptions annually, as reported by IQVIA. Arbli™ differentiates itself from current offerings that involve compounding from tablets, boasting reduced dosing volume and room temperature storage stability. Two USPTO patents strengthen its market position, both pending listing in the FDA Orangebook.
Arbli™ is approved for treating hypertension in patients over 6 years of age, reducing stroke risk in hypertensive patients with left ventricular hypertrophy, and managing diabetic nephropathy in type 2 diabetes patients. This broad approval allows Scienture to provide a treatment option across multiple patient populations with specific needs for a liquid formulation.
